z-logo
open-access-imgOpen Access
An Adjuvant Capsule in the Treatment of Pemphigus Vulgaris: A Novel Hypothesis
Author(s) -
Farideh Jowkar,
Nasrin Saki,
Sina Kardeh
Publication year - 2014
Publication title -
galen medical journal
Language(s) - English
Resource type - Journals
eISSN - 2588-2767
pISSN - 2322-2379
DOI - 10.31661/gmj.v3i3.263
Subject(s) - medicine , pemphigus vulgaris , adjuvant , acantholysis , pemphigus , immunology , immune system , antibody , autoantibody
Pemphigus vulgaris (PV) is one of the most common and studied autoimmune disorders of skin. The knock down of desmogleins in the skin by IgG antibodies will eventually leads to mucocutaneous problems in both genders. Targeting the cardinal molecules involved in the pathways of immune response is the main goal of given therapy. With regard to the side effects of long term use of immunosuppressive treatments, patients may use various adjuvant drug combinations. Sulfasalazine (SSZ) and Pentoxifylline (PTX) are two low-cost anti-TNF medications that can halt the acantholysis in PV. Tetracycline is an effective antibiotic with immunomdulatory properties on down-regulation of pro-inflammatory molecules such as NO, IL-1β. Moreover, the anti-inflammatory effects of Omega-3 take this supplement into account as a potential addition to anti-PV armamentarium. Thus, this complex could be utilized as a safe and effective adjuvant capsule against PV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here